1. Home
  2. LSF vs CTSO Comparison

LSF vs CTSO Comparison

Compare LSF & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Laird Superfood Inc.

LSF

Laird Superfood Inc.

HOLD

Current Price

$2.37

Market Cap

24.3M

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.72

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LSF
CTSO
Founded
2015
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Medical/Dental Instruments
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3M
45.9M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
LSF
CTSO
Price
$2.37
$0.72
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$12.00
$5.38
AVG Volume (30 Days)
118.3K
126.1K
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$48,146,862.00
$36,979,520.00
Revenue This Year
$18.05
$9.51
Revenue Next Year
$17.53
$24.40
P/E Ratio
N/A
N/A
Revenue Growth
17.73
23.89
52 Week Low
$2.18
$0.60
52 Week High
$8.99
$1.61

Technical Indicators

Market Signals
Indicator
LSF
CTSO
Relative Strength Index (RSI) 28.90 47.96
Support Level $2.18 $0.70
Resistance Level $2.78 $0.75
Average True Range (ATR) 0.19 0.07
MACD 0.05 0.01
Stochastic Oscillator 27.67 56.00

Price Performance

Historical Comparison
LSF
CTSO

About LSF Laird Superfood Inc.

Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: